A generous $100,000 gift from Jonathan and Hope Ashner was made to support the research of Elizabeth Buchbinder, MD. The gift will help to fuel Buchbinder’s groundbreaking investigations into melanoma and maximize progress against the disease.
Doron Broman, a Miami-based real estate developer and stage IV pancreatic cancer patient, has given $150,000 to support research in pancreatic cancer under the direction of Kimmie Ng, MD, MPH. Broman came to Dana-Farber in 2015 with only months to live, but under the treatment of Ng, has defied the odds and is celebrating seven years since his diagnosis.
Jeffrey and Jennifer Goldstein made a generous gift in support of Pasi Jänne, MD, PhD, director of the Carole M. and Philip L. Lowe Center for Thoracic Oncology at Dana-Farber. The gift will support Jänne and his team’s continued research into targeted therapies in lung cancer, novel EGFR inhibitors, and mechanisms of drug resistance, ultimately helping more patients and their families.
Matthew Miller gave $100,000 to advance groundbreaking investigations in melanoma led by Rizwan Haq, MD, PhD. Miller’s support will help Haq uncover the genomic intricacies of drug resistance and explore new ways to enhance personalized medicine for patients.
Dana-Farber recently received a $110,000 grant from the National Foundation for Cancer Research to study new, non-invasive approaches to identify specific subtypes of kidney cancer and particular genetic alterations in prostate cancer, with the aim of creating earlier detection and treatment interventions for patients with these diseases.
Load More Briefs
The American Association for Cancer Research (AACR) recently awarded $480,000 to four Dana-Farber physician-scientists who are investigating new methods of prevention, diagnosis, and treatment for various types of cancers. As the first cancer research organization dedicated to preventing and curing cancer, AACR is a long-standing partner in Dana-Farber’s mission to defy cancer.
The Glenn Foundation for Medical Research and the American Federation for Aging Research awarded a $300,000 grant to support basic science research by Dana-Farber’s Edward Chouchani, PhD, as he seeks to systematically define the functional targets of reactive oxygen species that contribute to longevity and age.
The B.A.A 5K® took place April 15, welcoming the largest team to date of Dana-Farber runners who collectively raised $184,271. Runners had the option to race in person on the 3.1-mile course that began and ended in the Boston Common, or run in their own neighborhoods as virtual teammates. The top fundraiser honor went to David Mullen.
Sandra Bornstein and her late husband, Richard, made a generous commitment of $400,000 to support early career physician-scientists on the leukemia and stem cell transplant teams at Dana-Farber. Faculty excellence is a top priority of The Dana-Farber Campaign, and this funding will help fuel the growth of promising investigators as they work to ensure greater numbers of patients live longer, healthier lives.
The Clifford Family established the Woolley-Clifford Foundation Fund with a $100,000 gift, supporting the research of David Kozono, MD, PhD, as he works to investigate blood and tissue-based biomarkers in lung cancer patients that can help predict lung inflammation and anti-tumor response following radiation therapy.
Load More Briefs
In 2022, Andrea McGrath celebrated 20 years since her successful stem cell transplant at Dana-Farber. She hosted a survivorship event, raising over $16,000 to benefit the work of her doctor and now friend, Corey Cutler, MD, MPH, FRCPC, whose advances in stem cell transplantation are continuing to improve outcomes for blood disorder patients like her.
3000 Miles to a Cure awarded $100,000 to support the ALLELE-GBM research program at Dana-Farber, under the direction of Keith Ligon, MD, PhD. Ligon’s team is working to put genomic data into the hands of patients, providers, and researchers to advance treatments and clinical trials in glioblastoma (GBM).
Barbara and Arnold Barron gave $100,000 to support lung cancer research under the direction of Michael Rabin, MD. The couple has supported the work of Rabin and Dana-Farber for many years, this gift marking their latest commitment to spur advancements in durable treatments for lung cancer patients at Dana-Farber and around the globe.
The Charles A. King Trust Postdoctoral Research Fellowship Program, administered by Health Resources in Action, awarded grants totaling $246,776 to two Dana-Farber fellows working in small cell lung cancer and leukemia, as part of the trust’s mission to promote the investigation of human disease, to alleviate suffering through improved treatment.
Children’s Cancer Research Fund awarded their Emerging Scientist Award to Dana-Farber pediatric oncologist Emily Heikamp, MD, PhD, MSc. The grant of $100,000 will support Heikamp’s work in uncovering therapeutic vulnerabilities in the NU98-r gene, which could lead to safer and more effective treatments for children with relapsed acute myeloid leukemia.
Load More Briefs
Margaret and Michael Bayer gave $100,000 to establish The Bayer Family Research Fund. The fund aims to accelerate discoveries into safer, more effective and durable treatments for patients facing Waldenström’s macroglobulinemia, a rare form of blood cancer.
The 2022 Boston Red Sox Jimmy Fund Award—the Jimmy Fund’s highest honor—was presented to John Berardi (second from right), program director of Jimmy Fund Little League presented by Franklin Sports, which rallies thousands of youth baseball and softball players each summer to fundraise for the Jimmy Fund in their communities and has raised over $6 million for Dana-Farber since 1986.
Breast Cancer Alliance awarded $125,000 to Dana-Farber to support research into the features of the tumor microenvironment that result in metastatic triple-negative breast cancer (TNBC). This work will improve researchers’ knowledge of the behavior of TNBC and may help identify patients who are more likely to benefit from treatments such as immunotherapy.
Fred and Michele Brettschneider made a commitment of $250,000 to support a clinical trial network for Waldenström’s macroglobulinemia and advance all clinical research for this rare form of blood cancer within the Bing Center for Waldenström’s Macroglobulinemia.
The Burlingame Foundation gave $300,000 to provide support for patient navigation through the Cancer Care Equity Program (CCEP). Patient navigation involves supporting and assisting patients through the complexities of treatment—a key component of the CCEP’s effort to address disparities in cancer care.
Load More Briefs